Stockscreener 앱 받기
24.62
1.28%
0.31
시간 외 거래:
24.84
0.22
+0.89%
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Barclays reiterates Overweight rating on Ultragenyx Pharma stock - Investing.com
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today - AOL.com
Precision Trading with Ultragenyx Pharmaceutical Inc. (RARE) Risk Zones - Stock Traders Daily
Ultragenyx Pharmaceutical's Phase III Study Fails to Meet Primary Endpoint, Analysts Cut Price Targets - Intellectia AI
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies - Sahm
Ultragenyx Pharmaceutical Inc. Faces Setback as Phase III Studies Fail to Meet Primary Endpoint - Intellectia AI
New Ultragenyx hires get 16,355 stock units vesting over 4 years - Stock Titan
Bone drug lifts density but not fractures, drawing Ultragenyx investor scrutiny - Stock Titan
Emerald Mutual Fund Advisers Trust Sells 52,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
Ultragenyx (RARE) Lifts 2025 Revenue Guidance, But What Does It Reveal About Growth Visibility? - Sahm
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring the 184% Potential Upside for Biotech Investors - directorstalkinterviews.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Lobbying Update: $60,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
2026-01-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | NDAQ:RARE | Press Release - Stockhouse
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Dividend Watch: What are the future prospects of Ultragenyx Pharmaceutical Inc2025 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion - Sahm
Will Ultragenyx Pharmaceutical Inc outperform tech stocksStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Quarterly Recap: Is Ultragenyx Pharmaceutical Inc stock ready for breakoutTrend Reversal & Daily Chart Pattern Signals - Bộ Nội Vụ
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? - Yahoo Finance
Ultragenyx reports preliminary 2025 revenue of $672-674 million By Investing.com - Investing.com Nigeria
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update - Yahoo Finance
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery - Insider Monkey
Ultragenyx reports preliminary 2025 revenue of $672-674 million - Investing.com
Ultragenyx Pharmaceutical Inc. Reports Preliminary 2025 Revenue of $672 Million to $674 Million, Exceeding Guidance - Quiver Quantitative
Ultragenyx provides financial and business updates at J.P. Morgan Annual Healthcare Conference - marketscreener.com
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - The Manila Times
SG Americas Securities LLC Purchases Shares of 125,429 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Analysts lower Ultragenyx (RARE) target but stay bullish - MSN
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission - MSN
Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges - MSN
Can Ultragenyx Pharmaceutical Inc. (UP0) stock beat analyst consensusEntry Point & Reliable Price Breakout Alerts - Улправда
Why Ultragenyx Pharmaceutical Inc. stock is trending among retail tradersPrice Action & Low Risk Entry Point Guides - ulpravda.ru
Can Ultragenyx Pharmaceutical Inc. stock rebound after recent weaknessMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish - Insider Monkey
Looking Into Ultragenyx Pharmaceutical Inc's Recent Short Interest - Sahm
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
RARE ALERT: Ongoing Investigation Into Ultragenyx Pharmaceutical Inc.Contact Levi & Korsinsky - ACCESS Newswire
Ongoing Investigation into Ultragenyx Pharmaceutical Inc. (RARE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
How Ultragenyx Pharmaceutical Inc. stock valuations compare to rivals2025 Volatility Report & Safe Entry Trade Reports - ulpravda.ru
2026-01-08 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
2.09%
0.48%
자본화:
|
볼륨(24시간):